Stock Events

Stock Events

Search...

ProMIS Neurosciences

€1.05

0

+€0+0% Today

Statistics

Day High

1.05

Day Low

1.05

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

36.04M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

13NovExpected

Q1 2024

Q2 2024

Next

-0.18

-0.14

-0.1

-0.06

Expected EPS

-0.06335070000000001

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 23J0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen is a direct competitor in the Alzheimer's disease treatment market, focusing on advanced biologics and therapies similar to ProMIS Neurosciences.

Eli Lilly is a competitor because of its significant investments in Alzheimer's disease research and development of related therapeutics, competing in the same space as ProMIS.

Pfizer has been involved in the development of treatments for neurological disorders, including Alzheimer's, making it a competitor in the neurodegenerative disease sector.

Merck & Co., Inc. competes in the Alzheimer's disease treatment market with its research and development efforts in neurodegenerative diseases.

AbbVie is involved in neuroscience and specifically Alzheimer's disease research, making it a competitor in the development of neurodegenerative disease treatments.

Novartis AG is a competitor due to its extensive research and development in neurodegenerative diseases, including Alzheimer's disease.

Acadia Pharmaceuticals

ACADIA Pharmaceuticals focuses on the central nervous system disorders, including Alzheimer's, making it a competitor in the neuroscience field.

Sage Therapeutics

Sage Therapeutics is involved in developing treatments for central nervous system disorders, positioning it as a competitor in the neurodegenerative disease market.

Ionis Pharmaceuticals

Ionis Pharmaceuticals, with its focus on RNA-targeted drug discovery and development, competes in the development of treatments for neurodegenerative diseases like Alzheimer's.

About

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Show more...

CEO

Mr. Eugene W. Williams

Employees

6

Country

CA

ISIN

CA74346M4065

WKN

000A3DM9Q

Listings